Statin

Statins, also known as HMG-CoA reductase inhibitors, are a class of medications designed to lower cholesterol levels in the blood. They are essential tools for managing cardiovascular disease, which involves problems with the heart and blood vessels. High levels of low-density lipoprotein (LDL) cholesterol are a major concern. LDL acts as a carrier for cholesterol in the bloodstream. According to the lipid hypothesis, these carriers play a key role in developing atherosclerosis. Atherosclerosis is the buildup of substances in the artery walls. This buildup can lead to coronary heart disease.

To understand how statins work, we must look at a specific biological process. The body produces cholesterol using a specific tool called an enzyme. This enzyme is named HMG-CoA reductase. It plays a central role in the production of cholesterol within the body. Statins work by inhibiting this enzyme. When the enzyme is inhibited, the production of cholesterol is slowed down.

This mechanism effectively lowers the amount of LDL cholesterol circulating in the blood. By reducing these levels, statins help prevent the dangerous buildup in the arteries.

There are several different types of statins available for medical use. Common examples include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. Some patients may even take combination preparations. For instance, a person might take a mixture of ezetimibe and simvastatin. Atorvastatin is particularly notable in the medical industry. It is also known by the name Lipitor. In 2003, it became the best-selling pharmaceutical in history. By the year 2008, its sales reached $12 billion. In the United States, sales were estimated at $5–$6 billion in 2024.

Medical professionals generally categorize the use of statins into two distinct strategies. The first is primary prevention. This is used for people who are at high risk for heart disease but have not developed it yet. Risk factors might include diabetes, high blood pressure, or smoking. Guidelines from the USPSTF recommend statins for adults aged 40 to 75 with a 10-year risk of 7.5% to 10% or greater. The second strategy is secondary prevention. This is for individuals who already have pre-existing cardiovascular disease. This might include a history of heart attack, stroke, or stable angina.

Statins provide significant benefits for many patients. On average, these medications can lower LDL cholesterol by 1.8 mmol/L (70 mg/dL). This reduction can lead to an estimated 60% decrease in cardiac events, such as heart attacks. Long-term treatment may also result in a 17% reduced risk of stroke. In the context of primary prevention, a 2013 Cochrane review suggested significant benefits. It noted that for every 49 people treated, one fewer has an episode of heart disease. These statistics highlight why statins are on the World Health Organization's List of Essential Medicines.

Despite these benefits, statins can cause side effects that require careful monitoring. Some patients experience muscle pain or an increased risk of diabetes. Statins can also cause abnormal levels of certain liver enzymes. These changes occur because inhibiting HMG-CoA reductase affects other processes. For example, it can impact the production of CoQ10, which is important for muscle function. In very rare cases, statins can cause severe muscle damage. This serious condition is known as rhabdomyolysis. Over five years of treatment, data shows about 5 cases of muscle damage per 10,000 people.

Statins are also studied in relation to other complex health conditions. For example, they may help reduce the risk of contrast-induced nephropathy. This is a kidney issue that can happen during coronary angiography. Research found that statins could reduce this risk by 53% in certain patients. There is also some low-quality evidence suggesting an adjunct role in treating asthma through anti-inflammatory pathways. Additionally, statins are used in people with familial hypercholesterolemia. This is a condition where people have genetic defects in their LDL receptors. While these patients may need high doses, statins remain a first-line treatment for them.